According to our (Global Info Research) latest study, the global Recombinant Human Follicle Stimulating Hormone Injection market size was valued at US$ 1420 million in 2025 and is forecast to a readjusted size of US$ 2014 million by 2032 with a CAGR of 5.2% during review period.
Recombinant follicle stimulating hormone is used in the treatment of female infertility and male hypogonadism. It is used in women who have a problem in ovulation or are undergoing fertility treatment like in-vitro fertilization. In men, it helps in the production of sperm cells.
Infertility affects many people at some point in their lives, according to a new report from the World Health Organization (WHO) released in 2023. About 17.5% of adults (about one in six people worldwide) experience infertility, highlighting the urgent need to expand access to affordable, high-quality reproductive health care for those who need it. Recombinant human follicle stimulating hormone is used in the treatment of female infertility and male hypogonadism. The safety and effectiveness of recombinant human follicle stimulating hormone have been verified in a large number of clinical applications. In the future, as biosimilar technology continues to mature and costs decrease, generic drugs will gradually break the market monopoly of original drugs and improve the accessibility of treatment. Generic drug companies will further enhance their market competitiveness by optimizing production processes, improving product quality and developing long-acting preparations.
This report is a detailed and comprehensive analysis for global Recombinant Human Follicle Stimulating Hormone Injection market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Recombinant Human Follicle Stimulating Hormone Injection market size and forecasts, in consumption value ($ Million), 2021-2032
Global Recombinant Human Follicle Stimulating Hormone Injection market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Recombinant Human Follicle Stimulating Hormone Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Recombinant Human Follicle Stimulating Hormone Injection market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Recombinant Human Follicle Stimulating Hormone Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Recombinant Human Follicle Stimulating Hormone Injection market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck KGaA, Organon, Gedeon Richter, Ferring, Changchun High-Tech, Theramex, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Recombinant Human Follicle Stimulating Hormone Injection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
75IU
150IU
300IU
Others
Market segment by Application
Women
Men
Market segment by players, this report covers
Merck KGaA
Organon
Gedeon Richter
Ferring
Changchun High-Tech
Theramex
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Recombinant Human Follicle Stimulating Hormone Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Recombinant Human Follicle Stimulating Hormone Injection, with revenue, gross margin, and global market share of Recombinant Human Follicle Stimulating Hormone Injection from 2021 to 2026.
Chapter 3, the Recombinant Human Follicle Stimulating Hormone Injection competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Recombinant Human Follicle Stimulating Hormone Injection market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Human Follicle Stimulating Hormone Injection.
Chapter 13, to describe Recombinant Human Follicle Stimulating Hormone Injection research findings and conclusion.
Summary:
Get latest Market Research Reports on Recombinant Human Follicle Stimulating Hormone Injection. Industry analysis & Market Report on Recombinant Human Follicle Stimulating Hormone Injection is a syndicated market report, published as Global Recombinant Human Follicle Stimulating Hormone Injection Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Recombinant Human Follicle Stimulating Hormone Injection market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.